{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:09:37Z","timestamp":1783951777284,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["K12HD043488"],"award-info":[{"award-number":["K12HD043488"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtha.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:07:58Z","timestamp":1730257678000},"page":"23-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["D\u00e9j\u00e0 vu all over again: a recurrent flaw in anticoagulant study design"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9981-8990","authenticated-orcid":false,"given":"Bethany","family":"Samuelson Bannow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.10.019_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.thromres.2015.07.030","article-title":"Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists","volume":"136","author":"De Crem","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.10.019_bib2","first-page":"1216","article-title":"Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data","volume":"190","author":"Warner","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2024.10.019_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.05.001","article-title":"Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism","volume":"93-95","author":"Godin","year":"2017","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2024.10.019_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102448","article-title":"Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial","volume":"8","author":"Hamuly\u00e1k","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.019_bib5","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jth.14226","article-title":"Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism","volume":"16","author":"Huisman","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.019_bib6","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/ph16060866","article-title":"Factor XIa inhibitors as a novel anticoagulation target: recent clinical research advances","volume":"16","author":"Xia","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtha.2024.10.019_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.019_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.10.019_bib9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.019_bib10","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.019_bib11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2024.10.019_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.vph.2016.11.003","article-title":"Heavy menstrual bleeding in women treated with rivaroxaban and vitamin K antagonists and the risk of recurrent venous thromboembolism","volume":"87","author":"Bryk","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.jtha.2024.10.019_bib13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.10.019_bib14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.thromres.2020.11.014","article-title":"Heavy menstrual bleeding in women on oral anticoagulants","volume":"197","author":"Samuelson Bannow","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2024.10.019_bib15","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1182\/blood.V122.21.4772.4772","article-title":"Establishment of a reference range for the PBAC-score","volume":"122","author":"Halimeh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.10.019_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/1471-0528.13273","article-title":"The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding","volume":"122","author":"Matteson","year":"2015","journal-title":"BJOG"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T02:38:38Z","timestamp":1767235118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624006354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1538783624006354"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.019","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9j\u00e0 vu all over again: a recurrent flaw in anticoagulant study design","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}